

Manufacturing, Quality and Supply Chain



Pfizer's global manufacturing and supply operation brings innovative therapies to the patients who need them.

Pfizer combines a global footprint – 63 manufacturing sites around the world under Pfizer Global Supply (PGS) – with technologically advanced production and cutting-edge tracking of supply to accelerate patient access. PGS colleagues are dedicated to getting medicines to patients and work closely with our research and development (R&D) partners to develop and deliver quality products that significantly improve patients' lives.

Expanding Biotechnology

In 2016, we announced our plans to invest approximately \$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in southeastern China. This will be Pfizer's third biotechnology center globally and the first in Asia, and is expected to be completed in 2018.

The Global Biotechnology Center will include an advanced, modular facility, created by our partner GE Healthcare, based on flexible, single-use bio-manufacturing technology that offers accelerated speed of construction and enhanced environmental standards.

The modular facility is particularly notable for its ability to increase speed-to-market and manufacturing flexibility, making it easier to develop and transfer products – at costs expected to be between 25 and 50 percent of equivalent traditional facilities. Additionally, the time it will take to build this facility is greatly shortened; just 18 months compared to three years for a conventional facility. Further, in keeping with Pfizer's Green Journey and commitment to environmental sustainability, the center is designed to reduce carbon dioxide emissions, water and energy usage as compared to traditional facilities.

Developing a State-of-the-Art Biologics Clinical Manufacturing Facility

In 2016, Pfizer broke ground on a new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company's presence in the state, Pfizer will invest more than \$200 million in the development of the 175,000-square foot, state-of-the-art facility that will help enable the production of high-quality, complex biologics and vaccines. The new building is expected to be operational by January 2019 and is expected to employ approximately 75 new employees to support clinical manufacturing.

Pfizer's Andover campus currently includes seven buildings housing laboratories, clinical and commercial manufacturing suites, and support areas. It also includes a multi-product manufacturing facility, which allows clinical and commercial products to be manufactured simultaneously, supporting a range of Pfizer product supply.



Accelerating the Supply Chain

Through our Highly Orchestrated Supply Network (HOSuN) approach, we have developed a supply chain that is directly sensitive to patient needs and can speed our response to those needs. Enhanced with technological advances, we are able to track movement of product throughout the entire supply chain. [Learn more about how HOSuN is accelerating patient impact and driving speed to delivery.](#)

In a year, Pfizer manufactured, packaged and distributed more than 74 billion units of product that helped patients in 129 countries around the world.

Global Supply Chain

In a year, Pfizer manufactured, packaged and distributed more than

74bn units across **125+** countries



Over

67bn

solid oral doses



Over

2bn

injectables



Over

135m

vaccines



Over

4bn

doses of other medicines

Note: some figures have been rounded for simplicity.

Our work in this area supports the United Nations' Sustainable Development Goals (SDGs), Goals 9 and 12. Find out more on page 34.